According to filings with the U.S. Securities and Exchange Commission, Baylor Genetics is raising up to $99,999,993.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Baylor Genetics
Baylor Genetics is a leading diagnostic genomics partner that has been driving innovation in precision diagnostics and pioneering genetic testing for nearly 50 years. The company offers a full spectrum of comprehensive genetic tests and diagnostic services, ranging from clinical-grade genomic sequencing to expert test interpretation, with a broad menu that includes whole genome sequencing, whole exome sequencing, chromosomal microarray analysis, and many other specialized assays. Positioned at the forefront of genomic research and clinical application, Baylor Genetics emphasizes translating cutting-edge science into clear, actionable answers for patients and healthcare providers, routinely presenting at major scientific conferences and publishing in respected journals such as the New England Journal of Medicine and Genome Medicine. Headquartered in Houston, Texas, the company operates a large, technologically advanced laboratory and provides services and support through dedicated client services, billing, and sample management teams to ensure timely, accurate, and accessible genetic insights. Through its long history and continued leadership in genomics, Baylor Genetics focuses on empowering patients with answers that matter and advancing the future of precision medicine.

To learn more, visit https://www.baylorgenetics.com/
LinkedIn: https://www.linkedin.com/company/baylorgenetics

Contact:
David Berger, Chief Legal Officer and Secretary

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.